Differences In Hemoglobin Levels, Erythrocyte Counts and Hematocrit Value in Kidney Failure Chronic Patients Pre and Post Erythropoietin Therapy
Perbedaan Kadar Hemoglobin, Jumlah Eritrosit dan Nilai Hematokrit pada Pasien Gagal Ginjal Kronik Pre dan Post Terapi Eritropoietin
DOI:
https://doi.org/10.21070/ups.5382Keywords:
Erythropoietin (EPO), Hemoglobin levels, Erythrocyte counts, Hematocrit ValuesAbstract
Kidney failure results in a decrease in erythropoietin, leading to the occurrence of anemia. Therefore, EPO therapy is given to increase Hb levels, erythrocyte count and hematocrit values. This study was to determine the difference in Hb levels, erythrocyte count and hematocrit values before and after administration of EPO in patients with kidney failure at Bangil Pasuruan Hospital in January-February 2024 The research design uses comparative analysis with the cross sectional method. Data were obtained from 45 results of examination of Hb levels, erythrocyte count and hematocrit values before and after EPO administration. Then the data was tested using the T dependent test. The significance value of Hb level was 0.021, the number of erythrocytes was 0.036 and the hematocrit value was 0.031. Because the sig value < 0.05, was concluded that there was a significant difference between Hb levels, erythrost count and hematocrit values before and after EPO therapy.
Downloads
References
KDIGO, “Clinical Practice Guideline for Evaluation and Management of Chronic Disease,” Kidney Int Suppl (2011), no. July, 2023.
T. S. Yeh, L. Clifton, J. A. Collister, X. Liu, D. J. Hunter, and T. J. Littlejohns, “Kidney function, albuminuria, and their modification by genetic factors and risk of incident dementia in UK Biobank,” Alzheimers Res Ther, vol. 15, no. 1, pp. 1–13, 2023, doi: 10.1186/s13195-023-01248-z.
T. Usherwood and V. Lee, “Advances in chronic kidney disease pathophysiology and management,” vol. 50, no. 4, pp. 188–192, 2021.
C. P. Kovesdy, “Epidemiology of chronic kidney disease: an update 2022,” Kidney Int Suppl (2011), vol. 12, no. 1, pp. 7–11, 2022, doi: 10.1016/j.kisu.2021.11.003.
PERNEFRI, “13th Annual Report of Indonesian Renal Registry 2020,” Indonesian Renal Registry (IRR), vol. 13, p. 11, 2020, [Online]. Available: https://www.indonesianrenalregistry.org/data/IRR 2018.pdf
J. Portolés, L. Martín, J. J. Broseta, and A. Cases, “Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents,” Front Med (Lausanne), vol. 8, no. March, pp. 1–14, 2021, doi: 10.3389/fmed.2021.642296.
A. Andika, Buku Ajar Hematologi. Sidoarjo: Umsida Press, 2019. doi: 10.21070/2019/978-623-7578-00-0.
G. Nugraha and I. Badrawi, “Pedoman Teknik Pemeriksaan Laboratorium Klinik,” Trans Info Media, p. 170, 2021.
R. N. Faizah, N. F. Azizah, and H. Purwoko, “Perbedaan Efektifitas Terapi Eritropoetin Alfa dan Beta Pada Pasien Hemodialisis Reguler di RSUD Sidoarjo,” Majalah Farmaseutik, vol. 18, no. 1, p. 65, 2022, doi: 10.22146/farmaseutik.v18i1.71914.
M. Purwiningtyas, Y. Yulistiani, B. Suprapti, and B. D. Santi, “Effectivity of Erythropoietin-Alpha between Fixed- and Adjusted-Dose in Chronic Kidney Disease Patients With Anemia on Hemodialysis,” Folia Medica Indonesiana, vol. 55, no. 4, p. 306, 2020, doi: 10.20473/fmi.v55i4.17334.
D. T. Untari, Buku Ajar Statistik 1, I. Banyumas: CV. Pena Persada, 2020.
R. Kurniawanto and U. M. Ninik, “STUDI PROFIL PENGGUNAAN ERITROPOETIN (EPO) PADA PASIEN PENYAKIT GINJAL KRONIS (PGK) YANG MENJALANI HEMODIALISA DI RUMAH SAKIT BHAYANGKARA H.S. SAMSOERI MERTOJOSO SURABAYA,” pp. 1–9, 2018.
N. Insani, M. A. Manggau, and H. Kasim, “Analisis Efektivitas Terapi Pada Pasien Anemia Gagal Ginjal Hemodialisis Di Rsup Dr. Wahidin Sudirohusodo Makassar,” Majalah Farmasi dan Farmakologi, vol. 22, no. 1, pp. 13–15, 2018, doi: 10.20956/mff.v22i1.5690.
M. P. Angin, N. Nofita, and L. C. Maharani, “EVALUASI KEBERHASILAN PENERAPAN TERAPI ESA (Erythropoietin Stimulating Agent) PADA PASIEN HEMODIALISA DI RSUD PRINGSEWU,” Jurnal Farmasi Malahayati, vol. 4, no. 1, pp. 53–60, 2021, doi: 10.33024/jfm.v4i1.4811.
J. Coronado Daza and Gu. Cuchi, “Gender differences in dose of erythropoietin to maintain hemoglobin target in hemodialysis patients,” Indian J Nephrol, vol. 29, no. 3, p. 160, 2019, doi: 10.4103/ijn.IJN_124_18.
I. D. Purnami, Y. P. Indriani, and D. R. Susilowati, “Pengaruh Pemberian Obat Asam Folat, Eritropoietin dan Kombinasi Asam Folat Eritropoietin dalam Meningkatkan Hemoglobin pada Pasien Hemodialisa di RSUD dr. Gunawan Mangunkusumo,” Indonesian Journal of Medical and Pharmaceutical Science (IJMPS), vol. 3, no. 1, pp. 22–29, 2024.
N. D. Kartikawati, T. M. Andayani, and D. Endarti, “Gambaran dan Luaran Klinik Terapi Anemia Pada Pasien Chronic Kidney Disease Dengan Hemodialisis Di RS PKU Muhammadiyah Yogyakarta,” Majalah Farmaseutik, vol. 19, no. 1, pp. 148–154, 2023, doi: 10.22146/farmaseutik.v19i1.74877.
Downloads
Additional Files
Posted
License
Copyright (c) 2024 UMSIDA Preprints Server
This work is licensed under a Creative Commons Attribution 4.0 International License.
